The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma

Laboratory Investigation

Volumn 88, Issue 8, 2008, Pages 873-882

  Sasaki, Motoko ^a   Ikeda, Hiroko ^a   Itatsu, Keita ^a   Yamaguchi, Junpei ^a   Sawada, Seiko ^a   Minato, Hiroshi ^a   Ohta, Tetsuo ^a   Nakanuma, Yasuni ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Bmi1; Combined hepatocellular and cholangiocarcinoma; Cytokeratin19; EZH2; Hepatocellular carcinoma; Polycomb group protein

Indexed keywords

BMI1 PROTEIN; POLYCOMB GROUP PROTEIN; POLYCOMB GROUP PROTEIN EZH2; SMALL INTERFERING RNA;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CARCINOMA CELL; CELL INFILTRATION; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL TYPE; CHOLANGIOCYTE; CONTROLLED STUDY; DYSPLASIA; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER CELL CARCINOMA; MALE; PRECANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; TUMOR VASCULARIZATION;

AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHOLANGIOCARCINOMA; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS;

EID: 48749104292     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2008.52     Document Type: Article

References (32)

1. Okuda K. Hepatocellular carcinoma. J Hepatol 2000;32(1 Suppl):225-237.
2. Wittekind C, Fischer H, Ponchon T. Combined Hepatocellular and Cholangiocarcinoma. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Digestive System. IARC Press: Lyon, 2000, pp 181-182.
3. Goodman ZD, Ishak KG, Langloss JM, et al. Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study. Cancer 1985;55:124-135.
4. Aishima S, Nishihara Y, Kuroda Y, et al. Histologic characteristics and prognostic significance in small hepatocellular carcinoma with biliary differentiation: subdivision and comparison with ordinary hepatocellular carcinoma. Am J Surg Pathol 2007;31:783-791.
5. Koh KC, Lee H, Choi MS, et al. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg 2005;189:120-125.
6. Kobayashi M, Ikeda K, Saitoh S, et al. Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis. Cancer 2000;88:2471-2477.
7. Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M. Stem cells and cancer; the polycomb connection. Cell 2004;118:409-418.
8. Park IK, Morrison SJ, Clarke MF. Bmi1, stem cells, and senescence regulation. J Clin Invest 2004;113:175-179.
9. Raaphorst FM, Otte AP, Meijer CJ. Polycomb-group genes as regulators of mammalian lymphopoiesis. Trends Immunol 2001;22:682-690.
10. Tateishi K, Ohta M, Kanai F, et al. Dysregulated expression of stem cell factor Bmi1 in precancerous lesions of the gastrointestinal tract. Clin Cancer Res 2006;12:6960-6966.
11. Gunster MJ, Raaphorst FM, Hamer KM, et al. Differential expression of human Polycomb group proteins in various tissues and cell types. J Cell Biochem 2001;81(S36):129-143.
12. Neo SY, Leow CK, Vega VB, et al. Identification of discriminators of hepatoma by gene expression profiling using a minimal dataset approach. Hepatology 2004;39:944-953.
13. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-629.
14. Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003;100:11606-11611.
15. Collett K, Eide GE, Arnes J, et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 2006;12:1168-1174.
16. Sudo T, Utsunomiya T, Mimori K, et al. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 2005;92:1754-1758.
17. Chen Y, Lin MC, Yao H, et al. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology 2007;46:200-208.
18. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 1995;22:983-993.
19. Hirohashi S, Ishak K, Kojiro M, et al. Hepatocellular carcinoma. In: Hamilton S, Aaltonen L (eds). Pathology and Genetics Tumours of the Digestive System World Health Organization of Tumours Liver Cancer. IARC Press: Lyon, 2000, pp 159-172.
20. Sasaki M, Ikeda H, Sato Y, et al. Decreased expression of Bmi1 is closely associated with cellular senescence in small bile ducts in primary biliary cirrhosis. Am J Pathol 2006;169:831-845.
21. Sasaki M, Van De Water J, Kenny TP, et al. Immunoglobulin gene usage and immunohistochemical characteristics of human monoclonal antibodies to the mitochondrial autoantigens of primary biliary cirrhosis induced in the XenoMouse. Hepatology 2001;34(Part 1):631-637.
22. Ma S, Chan KW, Hu L, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007;132:2542-2556.
23. Terada T, Terasaki S, Nakanuma Y. A clinicopathologic study of adenomatous hyperplasia of the liver in 209 consecutive cirrhotic livers examined by autopsy. Cancer 1993;72:1551-1556.
24. Nakanuma Y, Terada T, Ueda K, et al. Adenomatous hyperplasia of the liver as a precancerous lesion. Liver 1993;13:1-9.
25. Yuan RH, Jeng YM, Chen HL, et al. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol 2006;209:549-558.
26. Zeidler M, Kleer CG. The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer. J Mol Histol 2006;37:219-223.
27. Breuer RH, Snijders PJ, Smit EF, et al. Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia 2004;6:736-743.
28. Bracken AP, Kleine-Kohlbrecher D, Dietrich N, et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev 2007;21:525-530.
29. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005;115:1503-1521.
30. Lee JS, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006;12:410-416.
31. Cui H, Hu B, Li T, et al. Bmi-1 is essential for the tumorigenicity of neuroblastoma cells. Am J Pathol 2007;170:1370-1378.
32. Liu S, Dontu G, Mantle ID, et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 2006;66:6063-6071.